We need to use the best antiretroviral drugs worldwide to prevent HIV drug resistance

AIDS

Volumn 30, Issue 17, 2016, Pages 2725-2727

  Brenner, Bluma ^a   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

90 90 90; Antiretroviral drugs; Drug resistance

Indexed keywords

ANTIRETROVIRUS AGENT; BICTEGRAVIR; DOLUTEGRAVIR; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR ALAFENAMIDE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NOTE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SEXUAL TRANSMISSION; SEXUALITY; TREATMENT DURATION; VIRUS MUTATION; WORLD HEALTH ORGANIZATION; DRUG EFFECT;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS;

EID: 84996619313     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001234     Document Type: Note

References (15)

1. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342: 921-929.
2. Powers KA, Kretzschmar ME, Miller WC, Cohen MS. Impact of early-stage HIV transmission on treatment as prevention. Proc Natl Acad Sci U S A 2014; 111: 15867-15868.
3. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
4. Villabona-Arenas CJ, Vidal N, Guichet E, et al. In-depth analysis of HIV-1 drug resistance mutations in HIV-infected individuals failing first-line regimens in West and Central Africa. AIDS 2016; 30: 2577-2589.
5. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med 2011; 365: 637-646.
6. Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: An individual-patient- And sequence-level metaanalysis. PLoS Med 2015; 12: E1001810.
7. CohenMS, ChenYQ,McCauleyM,Gamble T,HosseinipourMC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016 [Epub ahead of print].
8. Hontelez JA, Chang AY, Ogbuoji O, Vlas SJ, Barnighausen T, Atun R. Changing HIV treatment eligibility under health system constraints in sub-Saharan Africa: Investment needs, population health gains, and cost-effectiveness. AIDS 2016[Epub ahead of print].
9. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double- blind, phase 3, noninferiority trials. Lancet 2015; 385: 2606-2615.
10. Cohn J, Bekker LG, Bygrave H, Calmy A. Hit me with your best shot: Dolutegravir - A space in the nextWHOguidelines? AIDS 2015; 29: 2067-2070.
11. Wainberg MA, Mesplede T, Raffi F. What if HIV were unable to develop resistance against a new therapeutic agent? BMC Med 2013; 11: 249-254.
12. Brenner BG, Wainberg MA. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Res 2016[Epub ahead of print].
13. Gallant J, Thompson Mills T, Dejesus E, Voskuhi G, Wei X, Zack J, et al. Novel Insti Gs-9883 10 day monotherapy in HIV-1 infected subjects. In: ASM Microbe Boston, MA, 16-20 June 2016.
14. Lazerwith SC, Cai R, Chen X, Chin G, Desai M, Eng S, et al. Discovery of Gs-9883, an HIV-1 integrase strand transfer inhibitor with improved pharmacokinetics and in vitro resistance profile. In: ASM Microbe. Boston, MA, 1-20 June 2016.
15. Zhang W, Hu M, Shi Y, Gong T, Dezzutti CS, Moncla B, et al. Vaginal microbicide film combinations of two reverse transcriptase inhibitors, EFdA and CSIC, for the prevention of HIV-1 sexual transmission. Pharm Res 2015; 32: 2960-2972.